Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab With or Without Sequential Intravesical GEM-MMC in BCG-Unresponsive/Intolerant HR-NMIBC
NCT07189793Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2026
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, gemcitabine, mitomycin c in non-muscle-invasive bladder cancer (NMIBC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
toripalimabgemcitabinemitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07189793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189793.